CY1115803T1 - MEASURES AND METHODS OF ACTION OF CELLULAR IMMUNE TREATMENT AGAINST CANCER USING VULNERABLE VOLUME KNOWLEDGE CELLS - Google Patents

MEASURES AND METHODS OF ACTION OF CELLULAR IMMUNE TREATMENT AGAINST CANCER USING VULNERABLE VOLUME KNOWLEDGE CELLS

Info

Publication number
CY1115803T1
CY1115803T1 CY20141101015T CY141101015T CY1115803T1 CY 1115803 T1 CY1115803 T1 CY 1115803T1 CY 20141101015 T CY20141101015 T CY 20141101015T CY 141101015 T CY141101015 T CY 141101015T CY 1115803 T1 CY1115803 T1 CY 1115803T1
Authority
CY
Cyprus
Prior art keywords
methods
vulnerable
measures
action
cellular immune
Prior art date
Application number
CY20141101015T
Other languages
Greek (el)
Inventor
Jirina Bartunková
Radek Spísek
Original Assignee
SOTIO a.s.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11172622A external-priority patent/EP2543386A1/en
Application filed by SOTIO a.s. filed Critical SOTIO a.s.
Publication of CY1115803T1 publication Critical patent/CY1115803T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Φέρονται στο προσκήνιο φαρμακευτικές συνθέσεις προς επαγωγή μίας ανοσοποιητικής απόκρισης έναντι κυττάρων όγκου οι οποίες συνθέσεις περιλαμβάνουν κύτταρα όγκου τα οποία καθίστανται αποπτωτικά μέσω κατεργασίας υπό μεγάλη υδροστατική πίεση και δενδριτικά κύτταρα, καθώς και μέθοδοι παραγωγής τέτοιων συνθέσεων.Pharmaceutical compositions are brought into the forefront to induce an immune response against tumor cells which compositions include tumor cells which become apoptotic by treatment under high hydrostatic pressure and dendritic cells, as well as methods of producing such compositions.

CY20141101015T 2011-07-05 2014-12-05 MEASURES AND METHODS OF ACTION OF CELLULAR IMMUNE TREATMENT AGAINST CANCER USING VULNERABLE VOLUME KNOWLEDGE CELLS CY1115803T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504387P 2011-07-05 2011-07-05
EP11172622A EP2543386A1 (en) 2011-07-05 2011-07-05 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
EP12734884.5A EP2691110B1 (en) 2011-07-05 2012-07-04 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Publications (1)

Publication Number Publication Date
CY1115803T1 true CY1115803T1 (en) 2017-01-25

Family

ID=50023029

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141101015T CY1115803T1 (en) 2011-07-05 2014-12-05 MEASURES AND METHODS OF ACTION OF CELLULAR IMMUNE TREATMENT AGAINST CANCER USING VULNERABLE VOLUME KNOWLEDGE CELLS

Country Status (7)

Country Link
JP (1) JP6235085B2 (en)
CL (1) CL2013003282A1 (en)
CY (1) CY1115803T1 (en)
HR (1) HRP20141230T1 (en)
IL (2) IL229702A (en)
MX (1) MX2013013243A (en)
ZA (1) ZA201307886B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012326203B2 (en) 2011-10-17 2017-11-30 Massachusetts Institute Of Technology Intracellular delivery
WO2015023982A1 (en) 2013-08-16 2015-02-19 Massachusetts Institute Of Technology Selective delivery of material to cells
RU2739794C2 (en) 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Delivery of biomolecules into cells of immune system
CN107002089B (en) 2014-11-14 2021-09-07 麻省理工学院 Disruption and field-effected delivery of compounds and compositions into cells
CA2971626A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
CA2988996A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056834A2 (en) * 1998-02-20 2000-12-06 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases

Also Published As

Publication number Publication date
IL229702A (en) 2016-09-29
CL2013003282A1 (en) 2014-10-10
JP6235085B2 (en) 2017-11-22
JP2017025066A (en) 2017-02-02
IL247781B (en) 2019-11-28
ZA201307886B (en) 2015-03-25
IL229702A0 (en) 2014-01-30
IL247781A0 (en) 2016-11-30
MX2013013243A (en) 2014-05-30
HRP20141230T1 (en) 2015-02-13

Similar Documents

Publication Publication Date Title
JOP20200192A1 (en) Anti-tigit antibodies
CY1115803T1 (en) MEASURES AND METHODS OF ACTION OF CELLULAR IMMUNE TREATMENT AGAINST CANCER USING VULNERABLE VOLUME KNOWLEDGE CELLS
PH12019501959A1 (en) Therapeutic rna
EA201990293A1 (en) MULTI-SPECIFIC ANTIBODIES AGAINST CD40 AND CD137
UA111738C2 (en) METHOD OF ACTIVE CANCER IMMUNOTHERAPY BY CANCER BY USING TUMOR CELLS DESTROYED BY HIGH HYDROSTATIC TISCODINE
WO2014018563A3 (en) Methods for the treatment of cancer
MY195167A (en) Modified Nucleotide Linkers
NZ739133A (en) Cellular targeted active ingredient delivery system
EA201291194A1 (en) INDONESIA
EA201400178A1 (en) BREAST CANCER TREATMENT
AR082340A1 (en) METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY
MX366804B (en) R-spondin translocations and methods using the same.
CL2017000506A1 (en) New anti-mfi2 antibodies and methods of use
EA201891601A1 (en) METHODS AND COMPOSITIONS ENHANCED EFFICIENCY BY MEDIATED SUPERANTIGEN IMMUNOTHERAPY OF MALIGNANT TUMORS
CY1121859T1 (en) METHOD OF PREPARATION OF GLYCOSYLOCERAMIDE SYNTHESIS INHIBITORS
EP3998341A3 (en) Adenoviral vectors
RU2012151073A (en) METHOD FOR STABILIZING A DIHYDROQUERCERETINE SOLUTION
MX2013003859A (en) Picropodophyllin polymorphs b or c for use in cancer therapy.
CY1118614T1 (en) NEW PRODUCERS (AZA) BENZHYDRATES, PROCESSING PROCESSES AND USE AS PROPOSED H4-RECEPTORS FOR THERAPEUTIC APPLICATIONS
NI201200183A (en) AN ANTI-TUMOR COMBINATION INCLUDING OMBRABULIN, A TAXANE DERIVATIVE AND A PLATINUM DERIVATIVE
TH149241B (en) Methods and methods for active cellular immunotherapies. To cure cancer By using tumor cells which were killed by high hydrostatic pressure And dendrite cells
UA101396U (en) A method of the intensive treatment of malignant tumors